TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28497534
Drug: Testosterone replacement
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone replacement therapy (TRT) - 250 mg of testosterone enanthate as an intramuscular injection every 4 weeks for 12 months
Study: 20403351
Drug: Indirab (Vero
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indirab (Vero cell based rabies vaccine)
Study: 20403351
Drug: Verorab (reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verorab (reference vaccine)
Study: 18689364
Drug: Diet S
Normalized name: Chewable Diet Supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet S (24 g soy protein and 70-80 mg isoflavones)
Study: 18689364
Drug: Diet SD
Normalized name: Alphanine SD
DrugBank: Coagulation Factor IX Human (DB13152)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet SD (12 g soy protein, 12 g dairy protein, and 70-80 mg isoflavones)
Study: 18689364
Drug: Diet D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet D (24 g dairy protein without isoflavones)
Study: 15844839
Drug: Xiong‐gui‐tiao‐xue‐yin (Kyuki‐chouketsu‐in)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xiong‐gui‐tiao‐xue‐yin (Kyuki‐chouketsu‐in) at a dose of 6.0 g/day
Study: 18420851
Drug: Droperidol 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 1.25 mg (group D)
Study: 11394426
Drug: Metoclopramide 10
Normalized name: metoclopramide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 10 mg (group M)
Study: 9891192
Drug: Buccal prochlorperazine
Normalized name: prochlorperazine Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal prochlorperazine
Study: 9891192
Drug: Oral prochlorperazine
Normalized name: Prochlorperazine
DrugBank: Prochlorperazine (DB00433)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prochlorperazine
Study: 2598991
Drug: Conventional formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional formulation of Carbamazepine (CBZ)
Study: 2598991
Drug: Controlled-release formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release formulation of Carbamazepine (CBZ)
Study: 371974
Drug: 2,3-dihydroxybenzoic acid
Normalized name: 2,3-dihydroxybenzoic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2,3-dihydroxybenzoic acid (2,3-DHB) at a dose of 25 mg/kg four times per day
Study: 28704936
Drug: Nutraceutical formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutraceutical formulation (berberine 200 mg, monacolin K 3 mg, chitosan 10 mg, coenzyme Q 10 mg)
Study: 19301720
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg once a day for five days
Study: 9921943
Drug: Sealed group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sealed group (povidone-iodine gel applied to subcutaneous tissue)
Study: 9921943
Drug: Open group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open group (usual treatment)
Study: 3281487
Drug: Proguanil (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proguanil (200 mg daily)
Study: 6152120
Drug: Chloroquine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine (300 mg weekly)
Study: 30443664
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of corticosteroid injections and strength training/stretching (n=29)
Study: 30443664
Drug: Corticosteroid injections
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injections (n=31)
Study: 26700861
Drug: PEG‐IFN alfa‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐IFN alfa‐2a therapy for 48 weeks
Study: 24340290
Drug: BBTI treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: BBTI treatment
Study: 17022791
Drug: Amisulpride 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride 150 mg/day
Study: 9926802
Drug: Implantable insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implantable insulin pump
Study: 9926802
Drug: Multiple daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily insulin injections
Study: 8067597
Drug: Azelastine, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine, 2 mg bid
Study: 8067597
Drug: Clemastine fumarate,
Normalized name: Clemastine Fumarate, compounding powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clemastine fumarate, 1.34 mg bid
Study: 28934950
Drug: Sham-acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham-acupuncture treatment
Study: 25797560
Drug: Rituximab plus
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab plus daily navitoclax for 12 weeks (arm B)
Study: 25797560
Drug: Rituximab plus
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab plus daily navitoclax until disease progression or unacceptable toxicity (arm C)
Study: 19695189
Drug: High-dose ganciclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ganciclovir (7.5 mg/kg in inducement phase, 10 mg/kg in maintaining phase)
Study: 19695189
Drug: Low-dose ganciclovir
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ganciclovir (5 mg/kg in inducement and maintaining phases)
Study: 17091363
Drug: Depressive symptoms
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depressive symptoms measured within 4 weeks after treatment
Study: 17091363
Drug: Treatment type
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment type (radical prostatectomy, external beam radiation, or brachytherapy)
Study: 14727275
Drug: 0.75 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mL/kg of bupivacaine 0.25% with ketamine 0.25 mg/kg
Study: 14727275
Drug: 0.75 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mL/kg of bupivacaine 0.25% with ketamine 0.5 mg/kg
Study: 14727275
Drug: 0.75 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mL/kg of bupivacaine 0.25% with ketamine 1 mg/kg
Study: 14727275
Drug: Group 1
Normalized name: Chlamydophila psittaci biogroup 1 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 (bupivacaine 0.25% with ketamine 0.25 mg/kg)
Study: 11349178
Drug: Conjugated estrogen
Normalized name: Conjugated estrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated estrogen (0.625 mg) and medroxyprogesterone acetate (5 mg)
Study: 11349178
Drug: 17beta-estradiol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17beta-estradiol (2 mg) and norethindrone acetate (1 mg)
Study: 9139489
Drug: Combined injection
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined injection of acellular pertussis-diphtheria-tetanus vaccine with Haemophilus influenzae b conjugate vaccine
Study: 8375540
Drug: Polyacrylamide gel
Normalized name: polyacrylamide (10000 MW)
DrugBank: Polyacrylamide (crosslinked; 2 mole percent bisacrylamide) (DB14771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyacrylamide gel (1.5%, 1.6%, 1.7%, 1.8%)
Study: 8375540
Drug: Polyacrylamide gel
Normalized name: polyacrylamide (10000 MW)
DrugBank: Polyacrylamide (crosslinked; 2 mole percent bisacrylamide) (DB14771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyacrylamide gel (1.8%)
Study: 26684594
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy (anti-impulse therapy)
Study: 23294276
Drug: Tofacitinib 2
Normalized name: tofacitinib 22 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 2 mg twice daily
Study: 18590518
Drug: Computerised cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerised cognitive behavioural therapy (CBT)
Study: 18590518
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual by a GP
Study: 18590518
Drug: Computerised cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerised cognitive behavioural therapy in combination with usual GP care
Study: 16092109
Drug: Long-term antiparkinson
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term antiparkinson therapy
Study: 16092109
Drug: Patients before
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients before therapy
Study: 12042268
Drug: Double lumen
Normalized name: SOLUPICC 7-Day Double Lumen PICC Line Supply Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double lumen catheter (CC)
Study: 10598602
Drug: Electrical stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrical stimulation for 0 min (sham treatment)
Study: 6087753
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of sulfamethoxazole and trimethoprim and ketoconazole
Study: 30449275
Drug: Fluralaner plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluralaner plus moxidectin (Bravecto® Plus) - minimum dose rates 40 mg/kg and 2 mg/kg, respectively
Study: 30449275
Drug: Emodepside plus
Normalized name: Emodepside
DrugBank: Emodepside (DB11403)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emodepside plus praziquantel (Profender®) - minimum dose rates 3 mg/kg and 12 mg/kg, respectively
Study: 27320173
Drug: Simvastatin plus
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin plus extended release niacin (ERN), 1500 to 2000 mg/day
Study: 22898678
Drug: Vandetanib 300
Normalized name: vandetanib 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vandetanib 300 mg per day
Study: 20693876
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg intravenous ketamine on induction of anesthesia and continuous infusion at 10 microg kg(‐1) min(‐1) until wound closure
Study: 20693876
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg intravenous ketamine
Study: 10561942
Drug: 0.05 per
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 per cent isotretinoin gel (Isotrex)
Study: 2070703
Drug: Amantadine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine (100 mg nocte)
Study: 1673628
Drug: Bromocriptine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (2.5 mg twice daily)
Study: 3053312
Drug: Cimetidine (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (800 mg nocte)
Study: 6680214
Drug: Topical sodium
Normalized name: sodium fluoride .0176 g in 1 g / HYDROFLUORIC ACID 0.010 g in 1 g DENTAL AEROSOL, FOAM [DENTI-CARE TOPICAL SODIUM FLUORIDE STRAWBERRY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical sodium fluoride gel
Study: 25548261
Drug: High-fat diet
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat diet (CETP rs3764261 CC genotype)
Study: 25548261
Drug: Low-fat diet
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat diet (CETP rs3764261 CC genotype)
Study: 25548261
Drug: Low-carbohydrate/high-fat weight-loss
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-carbohydrate/high-fat weight-loss diet (CETP rs3764261 CC genotype)
Study: 11694609
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (10 mg/d)
Study: 22414819
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (10 mg/d) after vitamin A supplementation (200,000 IU)
Study: 17595779
Drug: 7 or
Normalized name: Cyanocobalamin Co 57 Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 or more courses of intravenous topotecan
Study: 17595779
Drug: 6 or
Normalized name: Serc-16 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 or fewer courses of intravenous topotecan
Study: 17595779
Drug: topotecan treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: topotecan treatment
Study: 11991908
Drug: Laser therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser therapy (non-contact laser therapy)
Study: 7630998
Drug: Dance for
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dance for Health intervention (aerobic dance program, health education curriculum twice a week, dance-oriented physical education class three times a week)
Study: 22452620
Drug: Enteral nutrition
Normalized name: ENTERAL NUTRITION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral nutrition (35 kcal/Kg/day for 4 weeks followed by oral nutritional support for 2 months)
Study: 19167189
Drug: Combined transbuccal
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined transbuccal and intra-oral approach
Study: 19167189
Drug: Intra-oral alone
Normalized name: somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-oral alone
Study: 15364688
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of botulinum toxin type A
Study: 12324288
Drug: Dietary counseling
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary counseling with an extra 350 micro g folate derived from food/d
Study: 7857345
Drug: Pidotimod 800
Normalized name: pidotimod
DrugBank: Pidotimod (DB11364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pidotimod 800 mg sachets after fasting
Study: 7857345
Drug: Pidotimod 800
Normalized name: pidotimod
DrugBank: Pidotimod (DB11364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pidotimod 800 mg sachets after a standard meal
Study: 7857345
Drug: Pidotimod 800
Normalized name: pidotimod
DrugBank: Pidotimod (DB11364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pidotimod 800 mg ampoules after fasting
Study: 7857345
Drug: Pidotimod 800
Normalized name: pidotimod
DrugBank: Pidotimod (DB11364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pidotimod 800 mg ampoules after a standard meal
Study: 7857345
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of both formulations (sachets and ampoules)
Study: 2632449
Drug: Systemic aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic aspirin
Study: 662249
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of urea and prostaglandin
Study: 26571987
Drug: Ethanolic leaf
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanolic leaf extracts of Ocimum sanctum (EtOS) 300 mg per day for 30 days
Study: 22145768
Drug: Internet-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based treatment group
Study: 7505423
Drug: Aspartame (34
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspartame (34 mg/kg single morning dose)
Study: 27056638
Drug: Ipragliflozin 25-50
Normalized name: BEXAGLIFLOZIN
DrugBank: Bexagliflozin (DB12236)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipragliflozin 25-50 mg/day
Study: 27056638
Drug: Alogliptin 12.5-25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin 12.5-25 mg/day
Study: 20479759
Drug: Weekly high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly high-dose EPO for 3 months
Study: 18349391
Drug: Chemo-endocrine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemo-endocrine therapy (CMF chemotherapy for 6 cycles followed by goserelin)
Study: 18349391
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy alone (goserelin or tamoxifen)
Study: 18349391
Drug: Chemo-endocrine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemo-endocrine therapy (CMF followed by tamoxifen for 5 years)
Study: 14646613
Drug: etilevodopa/carbidopa swallowed
Approvals — FDA: no, EMA: no, PMDA: no
Description: etilevodopa/carbidopa swallowed tablets
Study: 14646613
Drug: etilevodopa/carbidopa tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: etilevodopa/carbidopa tablets dissolved in water
Study: 14646613
Drug: etilevodopa oral
Normalized name: etilevodopa
DrugBank: Etilevodopa (DB06535)
Approvals — FDA: no, EMA: no, PMDA: no
Description: etilevodopa oral solution with carbidopa tablets
Study: 14646613
Drug: standard levodopa/carbidopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard levodopa/carbidopa tablets
Study: 10961868
Drug: Weekly PEG‐Asp
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly PEG‐Asp dosing
Study: 1312773
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of folic acid daily for 6 months
Study: 22075942
Drug: Placebo daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily for 6 months
Study: 1289091
Drug: Supplementation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplementation of normal diet with 3 g of omega-3 polyunsaturated fatty acids per day for 6 months (treatment group)
Study: 1289091
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy only (control group)
Study: 2865857
Drug: Celiprolol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol (300 mg per day)
Study: 2865857
Drug: Propranolol (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (160 mg per day)
Study: 27100799
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Group Therapy (CBGT) for 12 weeks
Study: 22844979
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg ketamine lozenge
Study: 15949774
Drug: Conservative treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatments for low back pain
Study: 11908905
Drug: CLA supplementation
Normalized name: CLA
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CLA supplementation (1.5 g daily)
Study: 10096389
Drug: DHEA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA treatment (50 mg orally once a day for 6 months)
Study: 10096389
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (one time a day for 6 months)
Study: 30782991
Drug: Sequential CQ-PQ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential CQ-PQ treatment (arm 1)
Study: 30782991
Drug: Concomitant CQ-PQ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant CQ-PQ treatment (arm 2)
Study: 11439794
Drug: Morphine 1
Normalized name: morphine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 1 mg/ml (group M)
Study: 11439794
Drug: Morphine 1
Normalized name: morphine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 1 mg/ml plus ketamine 2 mg/ml (group K)
Study: 9492501
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection of buprenorphine 0.1-0.2 mg with 0.25% bupivacaine
Study: 9492501
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of buprenorphine 0.4 mg with 0.25% bupivacaine (40 ml at 1.7 ml.h-1)
Study: 3128112
Drug: Cefoxitin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin (3 doses of 2 gm: first 30-60 min before operation, then 6 and 12 hours later)
Study: 30690679
Drug: Fluoroscopy-guided intraarticular
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoroscopy-guided intraarticular shoulder injection (IAI)
Study: 24482140
Drug: Traditional analytic
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional analytic measures (e.g., participation rate, representativeness)
Study: 21714686
Drug: Genistein (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genistein (30 mg daily)
Study: 9048269
Drug: Methylnaltrexone 0.64
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylnaltrexone 0.64 mg/kg
Study: 9048269
Drug: Methylnaltrexone 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylnaltrexone 1.25 mg/kg
Study: 9048269
Drug: Methylnaltrexone 0.32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylnaltrexone 0.32 mg/kg
Study: 8322564
Drug: Intramuscular buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular buprenorphine (4 micrograms.kg‐1 body weight)
Study: 3524648
Drug: Zaprinast (M&B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zaprinast (M&B 22,948, a single oral dose)
Study: 31997490
Drug: Control (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (single antiplatelet therapy)
Study: 29502273
Drug: High-dose flavanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose flavanol
Study: 29502273
Drug: Low-dose flavanol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose flavanol
Study: 12835884
Drug: Disodium pamidronate
Normalized name: Disodium pamidronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium pamidronate (DP) 90 to 180 mg (stepwise increase) plus radiotherapy (30 Gy in ten fractions)
Study: 12835884
Drug: Disodium pamidronate
Normalized name: Disodium pamidronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium pamidronate (DP) 180 mg (flat dose) plus radiotherapy (30 Gy in ten fractions)
Study: 10680442
Drug: Flutrimazole 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutrimazole 1% cream
Study: 1726411
Drug: Selenium supplementation
Normalized name: Selenium supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium supplementation in the form of Se-yeast (200 micrograms daily) for 4 years
Study: 1726411
Drug: Selenium supplementation
Normalized name: Selenium supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium supplementation in the form of Se-yeast (200 micrograms daily) for 2 years
Study: 7254893
Drug: Specific therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific therapy
Study: 25432966
Drug: Probiotics treatment
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics treatment
Study: 22240593
Drug: Carvedilol CR
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol CR (10-80 mg/day)